In vivo pharmacokinetics of ginsenoside compound K mediated by gut microbiota

by Ming-Si Deng, Su-tian-zi Huang, Ya-Ni Xu, Li Shao, Zheng-Guang Wang, Liang-Jian Chen, Wei-Hua Huang

Ginsenoside Compound K (GCK) is the main metabolite of natural protopanaxadiol ginsenosides with diverse pharmacological effects. Gut microbiota contributes to the biotransformation of GCK, while the effect of gut microbiota on the pharmacokinetics of GCK in vivo remains unclear. To illustrate the role of gut microbiota in GCK metabolism in vivo, a systematic investigation of the pharmacokinetics of GCK in specific pathogen free (SPF) and pseudo-germ-free (pseudo-GF) rats were conducted. Pseudo-GF rats were treated with non-absorbable antibiotics. Liquid chromatography tandem mass spectrometry (LC–MS/MS) was validated for the quantification of GCK in rat plasma. Compared with SPF rats, the plasma concentration of GCK significantly increased after the gut microbiota depleted. The results showed that GCK absorption slowed down, T_max delayed by 3.5 h, AUC_0-11 increased by 1.3 times, CL_z/F decreased by 0.6 times in pseudo-GF rats, and C_max was 1.6 times higher than that of normal rats. The data indicated that gut microbiota played an important role in the pharmacokinetics of GCK in vivo.